SCHEMBL20334736

SCHEMBL20334736

B[C@@H]1O[C@H](COP(=O)(S)OC2C(OC)[C@H](B)O[C@@H]2CO)C(OS)C1OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736772 0.88 FBP1 (0.37) —
SCHEMBL24211093 0.83 — —
SCHEMBL20329196 0.83 — —
SCHEMBL26474225 0.83 — —
SCHEMBL24742680 0.79 LGALS8 (0.33) —
SCHEMBL19777495 0.79 LGALS8 (0.33) —
SCHEMBL24613864 0.78 — —
SCHEMBL23984435 0.77 FBP1 (0.34) —
SCHEMBL20329197 0.76 — —
SCHEMBL26474203 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10888578-B2 Exon skipping oligomer conjugates for muscular dystrophy SAREPTA THERAPEUTICS, INC. (US) 2021-01-12 — — US disclosed
US-20180177814-A1 EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2018-06-28 — — US disclosed
Send feedback